Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: MGV who wrote (1058)	4/14/1999 5:36:00 PM
From: MGV	Read Replies (2) \| Respond to of 1754

Revenue was $53.95M vs. GS' $52.8M and HQ's$53.1M estimates. As Charlie reported, bottom line was 4 cents over both consensus and the most bullish estimate, including GS' upward revision just 1 day ago. This continues to be a fast moving target. The only concern is GS' mention in its note yesterday that the "U.S. Patent Office has issued an initial office action on two of VISX's core patents" based on a request for a re-exammination by a "physician in Colorado, who claims to have access to prior art." According to GS "the patent re-exam includes the Trokel patent (5,108,388), which covers the broad area of refractive surgery using a laser and the Warner patent (4,903,695), which covers claims for LASIK." Further, according to GS, "in the initial office action, the patent office has rejected the claims of the patents - which is common with a patent re-examination. As part of the process, VISX will now be required to support its patent claims through written documentation in the next six months."